Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Net Income: 2020-2025

Historic Net Income for Rhythm Pharmaceuticals (RYTM) over the last 5 years, with Sep 2025 value amounting to -$52.9 million.

  • Rhythm Pharmaceuticals' Net Income fell 21.23% to -$52.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$192.3 million, marking a year-over-year increase of 25.72%. This contributed to the annual value of -$260.6 million for FY2024, which is 41.11% down from last year.
  • Rhythm Pharmaceuticals' Net Income amounted to -$52.9 million in Q3 2025, which was down 13.45% from -$46.6 million recorded in Q2 2025.
  • In the past 5 years, Rhythm Pharmaceuticals' Net Income ranged from a high of $43.8 million in Q1 2021 and a low of -$141.4 million during Q1 2024.
  • Its 3-year average for Net Income is -$54.0 million, with a median of -$46.6 million in 2025.
  • As far as peak fluctuations go, Rhythm Pharmaceuticals' Net Income skyrocketed by 228.06% in 2021, and later crashed by 220.07% in 2022.
  • Over the past 5 years, Rhythm Pharmaceuticals' Net Income (Quarterly) stood at -$50.9 million in 2021, then rose by 16.44% to -$42.5 million in 2022, then climbed by 2.02% to -$41.6 million in 2023, then fell by 3.98% to -$43.3 million in 2024, then declined by 21.23% to -$52.9 million in 2025.
  • Its last three reported values are -$52.9 million in Q3 2025, -$46.6 million for Q2 2025, and -$49.5 million during Q1 2025.